ClinicalTrials.gg
RecruitingNCT07718581Updated Oct 1, 2026

HMPL-A830 in Solid Tumors

A Phase 1/2 interventional study of HMPL-A830 and HMPL-A830 in Solid Tumor, Adult, sponsored by Hutchmed. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Hutchmed · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 1, 2026Now RecruitingFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
147
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH), multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A830 in participants with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors*, who are refractory or progressed on/after available standard treatment. The study will be conducted in 2 parts:

Dose Escalation (Part A, Phase I), approximately 57 participants will be enrolled.

Dose Optimization (Part B, Phase IIa), approximately 90 participants will be enrolled.

Read the detailed description

Part A: To evaluate the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for optimization (RDO) of HMPL-A830 in previously treated participants with solid tumors.

Part B: To characterize the safety, tolerability, and preliminary efficacy of HMPL-A830 at RDO(s) to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected solid tumors

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understood this study and are able to voluntarily sign the form (ICF);
  2. Male or Female, Age ≥ 18 years;
  3. Histological confirmed, unresectable, advanced or solid tumor
  4. Participants must have at least one per (RECIST) v1.1
  5. ≥ 12 weeks
  6. (ECOG) performance status (PS) of 0-1

Exclusion criteria

Exclusion Criteria:

  1. Use strong inhibitors of cytochrome P450 3A4 enzyme (), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug
  2. Major surgery within 28 days prior to the first dose of study drug
  3. Active infection requiring systemic treatment
  4. History of inflammatory gastrointestinal diseases
  5. Known to any component of HMPL-A830
  6. Pregnant (positive pregnancy test) or lactating;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
147 participants (estimated)

Study arms

  • Experimental
    Part A (Dose Escalation)

    Drug: HMPL-A830

  • Experimental
    Part B (Dose Optimization)

    Drug: HMPL-A830

Interventions

  • DrugHMPL-A830

    Enrolled participants with solid tumors will receive HMPL-A830 treatment in a dose escalation setting at 6 predefined dose levels

  • DrugHMPL-A830

    Participants will be randomized in a 1:1 ratio to receive treatment in two RDO levels. Randomization will be stratified by tumor types.

06

What researchers measure

Primary outcomes

  1. DLTs

    Number of Participants With of DLTs

    Time frame: Approximately 12 months

  2. Overview of Treatment-emergent Adverse Events (TEAEs)

    The number of participants with Adverse Events and Treatment-Related Adverse Events as Assessed by CTCAE v6.0

    Time frame: Approximately 12 months

  3. Objective Response Rate (ORR)

    Assessed by investigators according to RECIST 1.1

    Time frame: Approximately 24 months

  4. Recommended doses for phase II or III studies (RP2D or RP3D)

    The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data.

    Time frame: Approximately 12 months

Secondary outcomes

  1. Disease control rate (DCR)

    The DCR by RECIST 1.1

    Time frame: Approximately 2 years

  2. Progression-free survival (PFS)

    The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: Approximately 2 years

  3. Pharmacokinetic Analysis(Cmax)

    Maximum plasma concentration for HMPL-A830 (antibody drug conjugate, total antibody and payload)

    Time frame: Approximately 2 years

  4. Pharmacokinetic Analysis (Cmin)

    Trough concentration for HMPL-A830 (antibody drug conjugate, total antibody and payload)

    Time frame: Approximately 2 years

  5. Pharmacokinetic Analysis(Tmax)

    Time to reach maximum concentration for HMPL-A830 (antibody drug conjugate, total antibody and payload)

    Time frame: Approximately 2 years

  6. Pharmacokinetic Analysis((AUClast)

    Area under concentration-time curve from time zero to the last measurable concentration for HMPL-A830 (antibody drug conjugate, total antibody and payload)

    Time frame: Approximately 2 years

  7. Pharmacokinetic Analysis((AUCtau)

    Area under concentration-time curve from time zero to the end of the dosing interval for HMPL-A830 (antibody drug conjugate, total antibody and payload)

    Time frame: Approximately 2 years

  8. Incidence of anti-drug antibodies (ADAs) against HMPL-A830

    Number and percentage of patients developing anti-HMPL-A830 antibodies, and semiquantitative titer assessment.

    Time frame: Approximately 2 years

07

Study locations

4 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for May 2029, 31 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Aug 2026 → Sep 2026, primary completion Jun 2028 → May 2029 and completion Nov 2028 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 22, 2026
StartActual
Sep 24, 2026was Aug 2026
Primary completionEst.
May 23, 2029was Jun 2028
CompletionEst.
Dec 15, 2029was Nov 2028
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
7 sites added — first site in United States. 7 sites changed recruiting status (4 now recruiting, 3 now not yet recruiting)
Show 7 sites
  • Beijing Cancer Hospital · Beijing, Chinano status→Recruiting
  • Hunan Cancer Hospital · Changsha, Chinano status→Not yet recruiting
  • West China Hospital of Sichuan University · Chengdu, Chinano status→Not yet recruiting
  • The Sixth Affiliated Hospital,Sun Yat-sen University · Guangzhou, Chinano status→Recruiting
  • Shandong Cancer Hospital · Jinan, Chinano status→Recruiting
  • Jiangsu Province Hospital · Nanjing, Chinano status→Recruiting
  • Shanxi Provincial Cancer Hospitial · Taiyuan, Chinano status→Not yet recruiting
Show 7 added (6 United States, 1 China)
  • University of California Irvine Medical Center · Orange, United States
  • BRCR Global · Coral Springs, United States
  • Florida Clinical Trials Group · Plantation, United States
  • START New Jersey · East Brunswick, United States
  • SCRI Oncology Partners · Nashville, United States
  • START Mountain Region · West Valley City, United States
  • Jilin Cancer Hospital · Changchun, China
Oct 1, 2026
Start date
Aug 15, 2026→Sep 24, 2026 (actual)
Oct 1, 2026
Primary completion
Jun 26, 2028→May 23, 2029
Oct 1, 2026
Study completion
Nov 26, 2028→Dec 15, 2029
Oct 1, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Beijing Cancer Hospital · Beijing, ChinaContact none listed→•••9511Contact none listed→d•••@sina.cn
  • The Sixth Affiliated Hospital,Sun Yat-sen University · Guangzhou, ChinaContact none listed→•••6525Contact none listed→1•••@163.com
  • Shandong Cancer Hospital · Jinan, ChinaContact none listed→•••5936Contact none listed→n•••@163.com
  • Jiangsu Province Hospital · Nanjing, ChinaContact none listed→•••2066Contact none listed→X•••@126.com
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    7 sites added — first site in United States. 7 sites changed recruiting status (4 now recruiting, 3 now not yet recruiting)
    Show 7 sites
    • Beijing Cancer Hospital · Beijing, Chinano status→Recruiting
    • Hunan Cancer Hospital · Changsha, Chinano status→Not yet recruiting
    • West China Hospital of Sichuan University · Chengdu, Chinano status→Not yet recruiting
    • The Sixth Affiliated Hospital,Sun Yat-sen University · Guangzhou, Chinano status→Recruiting
    • Shandong Cancer Hospital · Jinan, Chinano status→Recruiting
    • Jiangsu Province Hospital · Nanjing, Chinano status→Recruiting
    • Shanxi Provincial Cancer Hospitial · Taiyuan, Chinano status→Not yet recruiting
    Show 7 added (6 United States, 1 China)
    • University of California Irvine Medical Center · Orange, United States
    • BRCR Global · Coral Springs, United States
    • Florida Clinical Trials Group · Plantation, United States
    • START New Jersey · East Brunswick, United States
    • SCRI Oncology Partners · Nashville, United States
    • START Mountain Region · West Valley City, United States
    • Jilin Cancer Hospital · Changchun, China
    Start date Aug 15, 2026→Sep 24, 2026 (now actual)
    Primary completion Jun 26, 2028→May 23, 2029
    Study completion Nov 26, 2028→Dec 15, 2029
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Beijing Cancer Hospital · Beijing, ChinaContact none listed→•••9511Contact none listed→d•••@sina.cn
    • The Sixth Affiliated Hospital,Sun Yat-sen University · Guangzhou, ChinaContact none listed→•••6525Contact none listed→1•••@163.com
    • Shandong Cancer Hospital · Jinan, ChinaContact none listed→•••5936Contact none listed→n•••@163.com
    • Jiangsu Province Hospital · Nanjing, ChinaContact none listed→•••2066Contact none listed→X•••@126.com
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07718581
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Sep 24, 2026
Primary completion
May 23, 2029 (estimated)
Completion
Dec 15, 2029 (estimated)
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion